Is Tumor Mutation Burden a predictive Marker for AJCC Stage II Melanoma?

被引：0
|
作者：
Sinnberg, T. [1 ]
Niessner, H. [1 ]
Amaral, T. [1 ,2 ]
Eigentler, T. [1 ]
Schroeder, C. [3 ]
Lindner, E. S. [3 ]
Hilke, F. J. [3 ,4 ]
Bonzheim, I. [5 ]
Fend, F. [5 ]
Riess, O. [3 ]
Garbe, C. [1 ]
机构：
[1] Univ Hautklin Tubingen, Zentrum Dermatoonkol, Tubingen, Germany
[2] Portuguese Air Force, Hlth Care Direct, Lisbon, Portugal
[3] Univ Klinikum Tubingen, Inst Med Genet & Angew Genom, Tubingen, Germany
[4] Charite Univ Med Berlin, Dermatol, Berlin, Germany
[5] Univ Klinikum Tubingen, Inst Pathol, Tubingen, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2020年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV34
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [31] Tumor mutational burden, as a potential predictive marker for the efficacy of immunotherapy in advanced gastric cancer
    Jang, Jaeyeon
    Jeon, Youngkyung
    Jeong, Sun Young
    Jung, Ye Ji
    Choi, Daeho
    Hong, Joohyun
    Lee, Jeeyun
    Kang, Won Ki
    Kim, Seung Tae
    CANCER RESEARCH, 2023, 83 (07)
  • [32] Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma
    Jiang, Feng
    Wu, Chuyan
    Wang, Ming
    Wei, Ke
    Zhou, Guoping
    Wang, Jimei
    CLINICA CHIMICA ACTA, 2020, 511 : 306 - 318
  • [33] Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanoma
    Zhang, Chuan
    Dang, Dan
    Liu, Chenlu
    Wang, Yuqian
    Cong, Xianling
    JOURNAL OF CANCER, 2021, 12 (08): : 2440 - 2449
  • [34] Discovery and validation of AMBLor as a prognostic biomarker for non-ulcerated cutaneous AJCC stage I/II melanoma
    Lovat, Penny
    Ewen, Tom
    Podlipnik, Sebastian
    Puig, Susana
    Malvehy, Josep
    Clark, Priscilla
    Lewis, Claire
    Paragh, Gyorgy
    Bogner, Paul
    Mailer, Sonia
    McArthur, Grant A.
    Husain, Akhtar
    Stefanos, Niki
    Barrett, Paul
    Labus, Marie
    Sloan, Philip
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma
    Hotz, Meghan J.
    O'Halloran, Eileen A.
    Hill, Maureen, V
    Hayden, Kelly
    Zaladonis, Angela G.
    Deng, Mengying
    Olszanski, Anthony J.
    Reddy, Sanjay S.
    Wu, Hong
    Luo, Biao
    Farma, Jeffrey M.
    MELANOMA RESEARCH, 2022, 32 (02) : 112 - 119
  • [36] Tumor Mutation Burden - PRO
    Sholl, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S246 - S246
  • [37] PD-L1 expression by tumor cell lines: A predictive marker in melanoma
    Knol, Anne C.
    Nguyen, Jean-Michel
    Pandolfino, Marie-Christine
    Denis, Marc G.
    Khammari, Amir
    Dreno, Brigitte
    EXPERIMENTAL DERMATOLOGY, 2018, 27 (06) : 647 - 655
  • [38] Primary Tumor Staining with ODAM, A Novel Biomarker, is Predictive for Stage III Melanoma
    Siddiqui, S.
    Gandhi, S. S.
    Bruker, C. T.
    Gray, K. D.
    Bell, J. L.
    Kestler, D.
    Lewis, J. M.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S107 - S108
  • [39] TERT promoter mutation subtypes and survival in stage I and II melanoma patients
    Andres-Lencina, Juan J.
    Rachakonda, Sivaramakrishna
    Garcia-Casado, Zaida
    Srinivas, Nalini
    Skorokhod, Alexander
    Requena, Celia
    Soriano, Virtudes
    Kumar, Rajiv
    Nagore, Eduardo
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (05) : 1027 - 1036
  • [40] Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy
    Lin, Po-Han
    Wang, Ming-Yang
    Lo, Chiao
    Tsai, Li-Wei
    Yen, Tzu-Chun
    Huang, Thomas Yoyan
    Huang, Wei-Chih
    Yang, Karen
    Chen, Chih-Kai
    Fan, Sheng-Chih
    Kuo, Sung-Hsin
    Huang, Chiun-Sheng
    FRONTIERS IN ONCOLOGY, 2021, 11
12345